• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Sarepta Therapeutics Set to Join S&P MidCap 400

    5/29/24 5:48:00 PM ET
    $JNJ
    $SPGI
    $SRPT
    $SWAV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Finance: Consumer Services
    Finance
    Get the next $JNJ alert in real time by email

    NEW YORK, May 29, 2024 /PRNewswire/ -- Sarepta Therapeutics Inc. (NASD: SRPT) will replace Shockwave Medical Inc. (NASD: SWAV) in the S&P MidCap 400 effective prior to the opening of trading on Monday, June 3. S&P 500 constituent Johnson & Johnson (NYSE:JNJ) is acquiring Shockwave Medical in a deal expected to be completed soon pending final closing conditions.

    Following is a summary of the changes that will take place prior to the open of trading on the effective date:

    Effective Date

    Index Name      

    Action

    Company Name

    Ticker

    GICS Sector

    June 3, 2024

    S&P MidCap 400

    Addition

    Sarepta Therapeutics

    SRPT

    Health Care

    June 3, 2024

    S&P MidCap 400

    Deletion

    Shockwave Medical

    SWAV

    Health Care

    For more information about S&P Dow Jones Indices, please visit www.spdji.com

    ABOUT S&P DOW JONES INDICES

    S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.

    S&P Dow Jones Indices is a division of S&P Global (NYSE:SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spdji.com.

    FOR MORE INFORMATION:

    S&P Dow Jones Indices

    [email protected]

    Media Inquiries

    [email protected]

    Cision View original content:https://www.prnewswire.com/news-releases/sarepta-therapeutics-set-to-join-sp-midcap-400-302158643.html

    SOURCE S&P Dow Jones Indices

    Get the next $JNJ alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $JNJ
    $SPGI
    $SRPT
    $SWAV

    CompanyDatePrice TargetRatingAnalyst
    Johnson & Johnson
    $JNJ
    4/8/2026$250.00Buy
    TD Cowen
    S&P Global Inc.
    $SPGI
    2/17/2026$575.00Buy
    BofA Securities
    Sarepta Therapeutics Inc.
    $SRPT
    1/28/2026$20.00Equal Weight
    Barclays
    Johnson & Johnson
    $JNJ
    1/28/2026$262.00Equal-Weight → Overweight
    Morgan Stanley
    Sarepta Therapeutics Inc.
    $SRPT
    12/9/2025$32.00Outperform
    Wedbush
    Johnson & Johnson
    $JNJ
    11/13/2025$230.00Sector Outperform
    Scotiabank
    Sarepta Therapeutics Inc.
    $SRPT
    11/5/2025$26.00Neutral → Outperform
    Mizuho
    Johnson & Johnson
    $JNJ
    10/20/2025$203.00Neutral → Outperform
    Daiwa Securities
    More analyst ratings

    $JNJ
    $SPGI
    $SRPT
    $SWAV
    SEC Filings

    View All

    SEC Form DEFA14A filed by S&P Global Inc.

    DEFA14A - S&P Global Inc. (0000064040) (Filer)

    3/31/26 8:09:51 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    SEC Form DEF 14A filed by S&P Global Inc.

    DEF 14A - S&P Global Inc. (0000064040) (Filer)

    3/31/26 8:05:43 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    Amendment: SEC Form SCHEDULE 13G/A filed by Sarepta Therapeutics Inc.

    SCHEDULE 13G/A - Sarepta Therapeutics, Inc. (0000873303) (Subject)

    3/27/26 1:00:25 PM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $SPGI
    $SRPT
    $SWAV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Robotics and AI in Drug Manufacturing: May Unlock Efficiency Gains, Long-Term Value

    AUSTIN, Texas, April 09, 2026 (GLOBE NEWSWIRE) -- AINewsWire Editorial Coverage: Pharmaceutical manufacturing is entering a period of structural transformation as regulators impose increasingly stringent expectations around contamination control, data integrity and operational traceability. The European Union's updated GMP Annex 1 guidance places strong emphasis on minimizing human involvement and implementing comprehensive contamination control strategies, requiring manufacturers to evaluate and mitigate risks across personnel, processes and environments. It also encourages the use of barrier systems and automation technologies, reflecting the widely accepted understanding that human oper

    4/9/26 8:30:00 AM ET
    $AMZN
    $JNJ
    $NVDA
    Catalog/Specialty Distribution
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care

    S&P Global Expands U.S. Employee Benefits By Matching Federal Government Contributions to Child Savings Accounts

    NEW YORK, April 7, 2026 /PRNewswire/ -- S&P Global (NYSE: SPGI) today announced it will match the U.S. government's $1,000 contributions to newly established Section 530A child savings accounts, commonly known as "Trump Accounts," for employees' eligible children born January 1, 2025, through December 31, 2028. The accounts, established under the Working Family Tax Cut initiative, are intended to help families build wealth over time through tax-advantaged savings and investment opportunities. S&P Global's matching program underscores the company's commitment to supporting employ

    4/7/26 6:55:00 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    Diebold Nixdorf Set to Join S&P SmallCap 600

    NEW YORK, April 7, 2026 /PRNewswire/ -- Diebold Nixdorf Inc. (NYSE:DBD) will replace Sealed Air Corp. (NYSE:SEE) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, April 10. Clayton, Dubilier & Rice LLC is acquiring Sealed Air in a deal expected to be completed April 9. Following is a summary of the changes that will take place prior to the open of trading on the effective date:Effective DateIndex Name       ActionCompany NameTickerGICS SectorApril 10, 2026S&P SmallCap 600AdditionDiebold NixdorfDBDInformation TechnologyApril 10, 2026S&P SmallCap 600DeletionSealed AirSEEMaterialsABOUT S&P DOW JONES INDICESS&P Dow Jones Indices is the largest global resource for essen

    4/7/26 5:47:00 PM ET
    $DBD
    $SEE
    $SPGI
    Office Equipment/Supplies/Services
    Miscellaneous
    Major Chemicals
    Industrials

    $JNJ
    $SPGI
    $SRPT
    $SWAV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    TD Cowen resumed coverage on Johnson & Johnson with a new price target

    TD Cowen resumed coverage of Johnson & Johnson with a rating of Buy and set a new price target of $250.00

    4/8/26 8:36:42 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BofA Securities resumed coverage on S&P Global with a new price target

    BofA Securities resumed coverage of S&P Global with a rating of Buy and set a new price target of $575.00

    2/17/26 7:30:15 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    Barclays resumed coverage on Sarepta Therapeutics with a new price target

    Barclays resumed coverage of Sarepta Therapeutics with a rating of Equal Weight and set a new price target of $20.00

    1/28/26 7:19:11 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $SPGI
    $SRPT
    $SWAV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Joly Hubert bought $997,459 worth of shares (2,500 units at $398.98), increasing direct ownership by 1,515% to 2,665 units (SEC Form 4)

    4 - S&P Global Inc. (0000064040) (Issuer)

    2/12/26 4:01:28 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    President, S&P Global Mobility Eager William W bought $11,917 worth of shares (23 units at $517.58), increasing direct ownership by 0.26% to 8,724 units (SEC Form 4)

    4 - S&P Global Inc. (0000064040) (Issuer)

    1/15/26 4:01:18 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    Director Weinberger Mark A bought $147,220 worth of shares (1,000 units at $147.22) (SEC Form 4)

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    12/12/24 5:27:36 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $SPGI
    $SRPT
    $SWAV
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for AMONDYS 45 issued to SAREPTA THERAPS INC

    Submission status for SAREPTA THERAPS INC's drug AMONDYS 45 (SUPPL-8) with active ingredient CASIMERSEN has changed to 'Approval' on 07/11/2024. Application Category: NDA, Application Number: 213026, Application Classification: Labeling

    7/12/24 4:40:36 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    June 20, 2024 - FDA Expands Approval of Gene Therapy for Patients with Duchenne Muscular Dystrophy

    For Immediate Release: June 20, 2024 Today, the U.S. Food and Drug Administration expanded the approval of Elevidys (delandistrogene moxeparvovec-rokl), a gene therapy for the treatment of Duchenne muscular dystrophy (DMD) for ambulatory and non-ambulatory individuals 4 years of age and older with DMD with a confirmed mutation in the DMD gene.  Elevidys was previously approved under accelerated approval for amb

    6/20/24 5:24:42 PM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VYONDYS 53 issued to SAREPTA THERAPS INC

    Submission status for SAREPTA THERAPS INC's drug VYONDYS 53 (SUPPL-11) with active ingredient GOLODIRSEN has changed to 'Approval' on 06/04/2024. Application Category: NDA, Application Number: 211970, Application Classification: Labeling

    6/5/24 4:41:31 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $SPGI
    $SRPT
    $SWAV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Craig Christopher

    4 - S&P Global Inc. (0000064040) (Issuer)

    4/2/26 5:01:52 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    Chief Operating Officer Estepan Ian Michael covered exercise/tax liability with 1,097 shares, decreasing direct ownership by 0.54% to 201,983 units (SEC Form 4)

    4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)

    3/13/26 8:09:03 PM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Wong Ryan Ho-Yan covered exercise/tax liability with 256 shares, decreasing direct ownership by 0.19% to 135,064 units (SEC Form 4)

    4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)

    3/13/26 8:07:03 PM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $SPGI
    $SRPT
    $SWAV
    Financials

    Live finance-specific insights

    View All

    S&P Global Schedules First Quarter 2026 Earnings Announcement and Conference Call for Tuesday, April 28, 2026

    NEW YORK, March 26, 2026 /PRNewswire/ -- S&P Global's (NYSE:SPGI) first quarter 2026 results will be issued on Tuesday, April 28, 2026 via news release at approximately 7:15 a.m. Eastern Daylight Time. The news release will be available at www.spglobal.com. Martina Cheung, President and CEO; Eric Aboaf, Chief Financial Officer; and Mark Grant, Senior Vice President, Investor Relations and Treasurer, will host a conference call and webcast at 8:30 a.m. Eastern Daylight Time on April 28, 2026 to discuss the Company's first quarter 2026 financial results.The presentation is open to all interested parties and may include forward-looking information. The presenters' slides, supplemental deck, and

    3/26/26 10:30:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    S&P Global Announces: Mobility Global to Host Investor Day on May 12, 2026

    NEW YORK, March 25, 2026 /PRNewswire/ -- S&P Global Inc. (NYSE:SPGI) announced today that its Mobility division ("Mobility Global") will host its inaugural Investor Day on May 12, 2026, in New York City, as it prepares for its planned separation from S&P Global into a standalone public company in mid-2026. Bill Eager, President of S&P Global Mobility and Chief Executive Officer of Mobility Global, will be joined by Matt Calderone, Chief Financial Officer-designate of Mobility Global, and other senior leaders to present the company's strategy, positioning, and financial framework

    3/25/26 9:16:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    S&P Dow Jones Indices Announces Change to the S&P/TSX Canadian Dividend Aristocrats Index

    TORONTO, March 24, 2026 /CNW/ - S&P Dow Jones Indices announces the following index change to the S&P/TSX Canadian Dividend Aristocrats Index as a result of the monthly dividend review. Change will be effective prior to the open of trading on Wednesday, April 1, 2026. S&P/TSX Canadian Dividend Aristocrats Index – April 1, 2026SymbolCOMPANYDELETEDGSYgoeasy Ltd.For more information about S&P Dow Jones Indices, please visit www.spdji.comABOUT S&P DOW JONES INDICESS&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are inv

    3/24/26 5:15:00 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    $JNJ
    $SPGI
    $SRPT
    $SWAV
    Leadership Updates

    Live Leadership Updates

    View All

    Diebold Nixdorf Set to Join S&P SmallCap 600

    NEW YORK, April 7, 2026 /PRNewswire/ -- Diebold Nixdorf Inc. (NYSE:DBD) will replace Sealed Air Corp. (NYSE:SEE) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, April 10. Clayton, Dubilier & Rice LLC is acquiring Sealed Air in a deal expected to be completed April 9. Following is a summary of the changes that will take place prior to the open of trading on the effective date:Effective DateIndex Name       ActionCompany NameTickerGICS SectorApril 10, 2026S&P SmallCap 600AdditionDiebold NixdorfDBDInformation TechnologyApril 10, 2026S&P SmallCap 600DeletionSealed AirSEEMaterialsABOUT S&P DOW JONES INDICESS&P Dow Jones Indices is the largest global resource for essen

    4/7/26 5:47:00 PM ET
    $DBD
    $SEE
    $SPGI
    Office Equipment/Supplies/Services
    Miscellaneous
    Major Chemicals
    Industrials

    Casey's General Stores Set to Join S&P 500; DigitalOcean Holdings to Join S&P MidCap 400; Broadstone Net Lease to Join S&P SmallCap 600

    NEW YORK, April 6, 2026 /PRNewswire/ -- S&P MidCap 400 constituent Casey's General Stores Inc. (NASD: CASY) will replace Hologic Inc. (NASD: HOLX) in the S&P 500, S&P SmallCap 600 constituent DigitalOcean Holdings Inc. (NYSE:DOCN) will replace Casey's General Stores in the S&P MidCap 400, and Broadstone Net Lease Inc. (NYSE:BNL) will replace DigitalOcean Holdings in the S&P SmallCap 600 effective prior to the opening of trading on Thursday, April 9. Affiliates of Blackstone Inc. and TPG Global are acquiring Hologic in a deal expected to be completed on or about April 7. Following is a summary of the changes that will take place prior to the open of trading on the effective date:Effective Dat

    4/6/26 5:51:00 PM ET
    $BNL
    $CASY
    $DOCN
    Real Estate Investment Trusts
    Real Estate
    Retail-Auto Dealers and Gas Stations
    Consumer Discretionary

    S&P Global Mobility Announces Appointment of Renato Negro as Chief Accounting Officer for Standalone Company

    NEW YORK, April 6, 2026 /PRNewswire/ -- S&P Global Mobility ("Mobility Global") today announced the appointment of Renato Negro as Chief Accounting Officer effective April 6, 2026. Mr. Negro will lead organization-wide accounting, tax, financial reporting, and compliance for Mobility Global following its planned separation into a standalone public company. He will report to Matt Calderone, who will serve as Chief Financial Officer of Mobility Global. S&P Global expects to complete the separation of the Mobility business in mid-2026, subject to the satisfaction of customary legal and regulatory requirements and approvals, including final approval by the S&P Global Board of Directors and the F

    4/6/26 8:42:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    $JNJ
    $SPGI
    $SRPT
    $SWAV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sarepta Therapeutics Inc.

    SC 13G/A - Sarepta Therapeutics, Inc. (0000873303) (Subject)

    11/13/24 10:27:59 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Johnson & Johnson

    SC 13G - JOHNSON & JOHNSON (0000200406) (Filed by)

    4/10/24 5:12:55 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by ShockWave Medical Inc. (Amendment)

    SC 13G/A - Shockwave Medical, Inc. (0001642545) (Subject)

    2/13/24 5:13:59 PM ET
    $SWAV
    Medical/Dental Instruments
    Health Care